• 1
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 2
    Winfield JB, Faiferman I, Koffler D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus: association with high avidity anti-native DNA antibody with glomerulonephritis. J Clin Invest 1977; 59: 906.
  • 3
    Smeenk RJ, van den Brink HG, Brinkman K, Termaat RM, Berden JH, Swaak AJ. Anti-dsDNA: choice of assay in relation to clinical value. Rheumatol Int 1991; 11: 1017.
  • 4
    Ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti–double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: a long-term, prospective study. Arthritis Rheum 1990; 33: 63443.
  • 5
    Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al, and the European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 5-year period: a multicenter prospective study of 1,000 patients. Medicine (Baltimore) 1999; 78: 16775.
  • 6
    Swaak AJ, Groenwald J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986; 45: 35966.
  • 7
    Ravirajan CT, Rowse L, MacGowan JR, Isenberg DA. An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study. Rheumatology (Oxford) 2001; 40: 140512.
  • 8
    Hahn BH. Antibodies to DNA. N Engl J Med 1998; 338: 135968.
  • 9
    Schur PH, Sandson J. Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 1968; 278: 5338.
  • 10
    Tojo T, Friou GJ. Lupus nephritis: varying complement-fixing properties of immunoglobulin G antibodies to antigens of cell nuclei. Science 1968; 161: 9046.
  • 11
    Lefkowith JB, Kiehl M, Rubenstein J, DiValerio R, Bernstein K, Kahl L, et al. Heterogeneity and clinical significance of glomerular-binding antibodies in systemic lupus erythematosus. J Clin Invest 1996; 98: 137380.
  • 12
    Brinkman K, Termaat R, Berden JH, Smeenk RJ. Anti-DNA antibodies and lupus nephritis: the complexity of crossreactivity. Immunol Today 1990; 11: 2324.
  • 13
    Deocharan B, Qing X, Lichauco J, Putterman C. α-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. J Immunol 2002; 168: 30728.
  • 14
    Koffler D, Schur PH, Kunkel HG. Immunological studies concerning the nephritis of systemic lupus erythematosus. J Exp Med 1967; 126: 60723.
  • 15
    Mannik M, Merrill CE, Stamps LD, Wener MH. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1495504.
  • 16
    Sabbaga J, Pankewycz OG, Lufft V, Schwartz RS, Madaio MP. Cross-reactivity distinguishes serum and nephritogenic anti-DNA antibodies in human lupus from their natural counterparts in normal serum. J Autoimmun 1990; 3: 21535.
  • 17
    Kohro-Kawata J, Wang P, Kawata Y, Matsuzaki M, Nakamura K. Highly cationic anti-DNA antibodies in patients with lupus nephritis analyzed by two-dimensional electrophoresis and immunoblotting. Electrophoresis 1998; 19: 15115.
  • 18
    Quismorio FP Jr. Clinical application of serologic abnormalities in systemic lupus erythematosus. In: WallaceDJ, HahnBH, editors. Dubois' lupus erythematosus. 5th ed. Baltimore: Williams & Wilkins; 1997. p. 92542.
  • 19
    Bijl M, Horst G, Bootsma H, Limburg PC, Kallenberg CG. Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 2003; 62: 5349.
  • 20
    Bootsma H, Spronk P, Derksen R, de Boer G, Wolters-Dicke H, Hermans J, et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345: 15959.
  • 21
    Ho A, Magder LS, Barr SG, Petri M. Decreases in anti–double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 23429.
  • 22
    Bijl M, Dijstelbloem HM, Oost WW, Bootsma H, Derksen RH, Aten J, et al. IgG subclass distribution of autoantibodies differs between renal and extra-renal relapses in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2002; 41: 627.
  • 23
    Gladman DD, Hirani N, Ibanez D, Urowitz MB. Clinically active serologically quiescent systemic lupus erythematosus. J Rheumatol 2003; 30: 19602.
  • 24
    Garin EH, Donnelly WH, Shulman ST, Fernandez R, Finton C, Williams RL, et al. The significance of serial measurements of serum complement C3 and C4 components and DNA binding capacity in patients with lupus nephritis. Clin Nephrol 1979; 12: 14855.
  • 25
    Swaak AJ, Aarden LA, Statius van Eps LW, Feltkamp TE. Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum 1979; 22: 22635.
  • 26
    Weinstein A, Bordwell B, Stone B, Tibbetts C, Rothfield NF. Antibodies to native DNA and serum complement (C3) levels: application to diagnosis and classification of systemic lupus erythematosus. Am J Med 1983; 74: 20616.
  • 27
    Petri M, Genovese M, Engle E, Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus: a prospective cohort study. Arthritis Rheum 1991; 34: 93744
  • 28
    Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D. Laboratory tests as predictors of disease exacerbation in systemic lupus erythematosus: why some tests fail. Arthritis Rheum 1996; 39: 3708.
  • 29
    Alarcon-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V, et al, and the LJP 394 Investigator Consortium. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003; 48: 44254.
  • 30
    Weisman MH, Bluestein HG, Berner CM, de Haan HA. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 1997; 24: 31438.
  • 31
    Furie RA, Cash JM, Cronin ME, Katz RS, Weisman MH, Aranow C, et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 2001; 28: 25765.
  • 32
    Sem DS, McNeeley PA, Linnik MD. Antibody affinities and relative titers in polyclonal populations: surface plasmon resonance analysis of anti-DNA antibodies. Arch Biochem Biophys 1999; 372: 628.
  • 33
    McNeeley PA, Iverson GM, Furie RA, Cash JM, Cronin ME, Katz RS, et al. Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients. Lupus 2001; 10: 52632.
  • 34
    Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Hura C, Strand V, et al. Clinical efficacy results from a RCT of LJP 394 in SLE patients with history of renal disease [abstract]. Arthritis Rheum 2003; 48 Suppl 9: S582.
  • 35
    Cox DR, Oaks D. Analysis of survival data. New York: Chapman and Hall; 1984.
  • 36
    Manger K, Manger B, Repp R, Geisselbrecht M, Geiger A, Pfahlberg A, et al. Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 2002; 61: 106570.
  • 37
    Huong DL, Papo T, Beaufils H, Wechsler B, Bletry O, Baumelou A, et al. Renal involvement in systemic lupus erythematosus: a study of 180 patients from a single center. Medicine (Baltimore) 1999; 78: 14866.
  • 38
    Barr RG, Seliger S, Appel GB, Zuniga R, D'Agati V, Salmon J, et al. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant 2003; 18: 203946.
  • 39
    Ho A, Barr SG, Magder LS, Petri M. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 2001; 44: 23507.
  • 40
    Cortes-Hernandez J, Ordi-Ros J, Labrador M, Segarra A, Tovar JL, Balada E, et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003; 12: 28796.
  • 41
    Ioannidis JP, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, Boletis JN, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57: 25864.
  • 42
    Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD, and the Lupus Nephritis Collaborative Study Group. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000; 35: 90414.
  • 43
    Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C. “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996; 50: 204753.
  • 44
    Ward MM. Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995. Arch Intern Med 2000; 160: 313640.
  • 45
    Jones DS, Hachmann JP, Osgood SA, Hayag MS, Barstad PA, Iverson GM, et al. Conjugates of double-stranded oligonucleotides with poly(ethylene glycol) and keyhole limpet hemocyanin: a model for treating systemic lupus erythematosus. Bioconjug Chem 1994; 5: 3909.